BACKGROUND: The optimal antithrombotic therapy to accompany tenecteplase in cases of acute ST-segment elevation myocardial infarction (STEMI) remains unclear. We undertook a prespecified pooled analysis of data from the ASSENT-3 and ASSENT-3 PLUS trials. METHODS: We created a combined database of the 2040 and 818 patients who received enoxaparin in ASSENT-3 and ASSENT-3 PLUS, respectively, and compared them with the 2038 and 821 patients who received unfractionated heparin. RESULTS: The efficacy end point (a composite of 30-day mortality, reinfarction or refractory ischemia) was 12.2% with enoxaparin versus 16.0% with unfractionated heparin (p < 0.001); the combined end point of efficacy plus safety (a composite of 30-day mortality, reinfarction, refractory ischemia, intracranial hemorrhage [ICH] or major systemic bleeding) was 15.0% versus 18.0%, respectively (p = 0.003) [corrected] The 1049 patients urgently revascularized had greater benefit from enoxaparin (15.4% v. 10.1%, p = 0.013), yet the excess in major systemic bleeding evident with enoxaparin (3.3% v. 2.4%, p = 0.01) was largely confined to the 3492 patients without or before revascularization. Although ICH rates in the groups were similar (1.3% v. 0.9%, p = 0.26), an excess of ICH occurred among those administered enoxaparin during the ASSENT-3 PLUS trial (6.7% v. 0.8%, p = 0.013), especially among women over 75 years of age. INTERPRETATION: These data demonstrated the benefit of enoxaparin used in conjunction with tenecteplase, but raised caution about its prehospital use to treat STEMI in elderly women.
BACKGROUND: The optimal antithrombotic therapy to accompany tenecteplase in cases of acute ST-segment elevation myocardial infarction (STEMI) remains unclear. We undertook a prespecified pooled analysis of data from the ASSENT-3 and ASSENT-3 PLUS trials. METHODS: We created a combined database of the 2040 and 818 patients who received enoxaparin in ASSENT-3 and ASSENT-3 PLUS, respectively, and compared them with the 2038 and 821 patients who received unfractionated heparin. RESULTS: The efficacy end point (a composite of 30-day mortality, reinfarction or refractory ischemia) was 12.2% with enoxaparin versus 16.0% with unfractionated heparin (p < 0.001); the combined end point of efficacy plus safety (a composite of 30-day mortality, reinfarction, refractory ischemia, intracranial hemorrhage [ICH] or major systemic bleeding) was 15.0% versus 18.0%, respectively (p = 0.003) [corrected] The 1049 patients urgently revascularized had greater benefit from enoxaparin (15.4% v. 10.1%, p = 0.013), yet the excess in major systemic bleeding evident with enoxaparin (3.3% v. 2.4%, p = 0.01) was largely confined to the 3492 patients without or before revascularization. Although ICH rates in the groups were similar (1.3% v. 0.9%, p = 0.26), an excess of ICH occurred among those administered enoxaparin during the ASSENT-3 PLUS trial (6.7% v. 0.8%, p = 0.013), especially among women over 75 years of age. INTERPRETATION: These data demonstrated the benefit of enoxaparin used in conjunction with tenecteplase, but raised caution about its prehospital use to treat STEMI in elderly women.
Authors: T J Ryan; E M Antman; N H Brooks; R M Califf; L D Hillis; L F Hiratzka; E Rapaport; B Riegel; R O Russell; E E Smith; W D Weaver; R J Gibbons; J S Alpert; K A Eagle; T J Gardner; A Garson; G Gregoratos; S C Smith Journal: Circulation Date: 1999-08-31 Impact factor: 29.690
Authors: John G Canto; Robert J Zalenski; Joseph P Ornato; William J Rogers; Catarina I Kiefe; David Magid; Michael G Shlipak; Paul D Frederick; Costas G Lambrew; Katherine A Littrell; Hal V Barron Journal: Circulation Date: 2002-12-10 Impact factor: 29.690
Authors: M L Simoons; A P Maggioni; G Knatterud; J D Leimberger; P de Jaegere; R van Domburg; E Boersma; M G Franzosi; R Califf; R Schröder Journal: Lancet Date: 1993 Dec 18-25 Impact factor: 79.321
Authors: F Van De Werf; J Adgey; D Ardissino; P W Armstrong; P Aylward; G Barbash; A Betriu; A S Binbrek; R Califf; R Diaz; R Fanebust; K Fox; C Granger; J Heikkilä; S Husted; P Jansky; A Langer; E Lupi; A Maseri; J Meyer; J Mlczoch; D Mocceti; D Myburgh; A Oto; E Paolasso; K Pehrsson; R Seabra-Gomes; L Soares-Piegas; D Sùgrue; M Tendera; E Topol; P Toutouzas; A Vahanian; F Verheugt; L Wallentin; H White Journal: Lancet Date: 1999-08-28 Impact factor: 79.321
Authors: L Wallentin; P Goldstein; P W Armstrong; C B Granger; A A J Adgey; H R Arntz; K Bogaerts; T Danays; B Lindahl; M Mäkijärvi; F Verheugt; F Van de Werf Journal: Circulation Date: 2003-07-07 Impact factor: 29.690
Authors: Henning R Andersen; Torsten T Nielsen; Klaus Rasmussen; Leif Thuesen; Henning Kelbaek; Per Thayssen; Ulrik Abildgaard; Flemming Pedersen; Jan K Madsen; Peer Grande; Anton B Villadsen; Lars R Krusell; Torben Haghfelt; Preben Lomholt; Steen E Husted; Else Vigholt; Henrik K Kjaergard; Leif Spange Mortensen Journal: N Engl J Med Date: 2003-08-21 Impact factor: 91.245
Authors: Elliott M Antman; David A Morrow; Carolyn H McCabe; Sabina A Murphy; Mikhail Ruda; Zygmunt Sadowski; Andrzej Budaj; Jose L López-Sendón; Sema Guneri; Frank Jiang; Harvey D White; Keith A A Fox; Eugene Braunwald Journal: N Engl J Med Date: 2006-03-14 Impact factor: 91.245
Authors: P Widimský; T Budesínský; D Vorác; L Groch; M Zelízko; M Aschermann; M Branny; J St'ásek; P Formánek Journal: Eur Heart J Date: 2003-01 Impact factor: 29.983
Authors: Karen S Pieper; Anastasios A Tsiatis; Marie Davidian; Vic Hasselblad; Neal S Kleiman; Eric Boersma; Wei-Ching Chang; Jeffrey Griffin; Paul W Armstrong; Robert M Califf; Robert A Harrington Journal: Circulation Date: 2004-02-10 Impact factor: 29.690
Authors: Robert C Welsh; Cynthia M Westerhout; Christopher E Buller; Blair O'Neill; Phillip Gordon; Paul W Armstrong Journal: J Thromb Thrombolysis Date: 2012-07 Impact factor: 2.300
Authors: Rober C Welsh; Luc Sauriol; Zugui Zhang; Paul Kolm; Willian S Weintraub; Pierre Theroux Journal: Can J Cardiol Date: 2009-12 Impact factor: 5.223